Change from Baseline in PROs at 16 and 24 Weeks
| PRO | Week 16 (total population) | Week 24 (responder analysis) | ||
|---|---|---|---|---|
| Abatacept | Placebo | Abatacept | Placebo | |
| SF-36 | n=202 | n=186 | n=124 | n=97 |
| PCS | 3.76 (0.55)* | 2.02 (0.57) | 5.11 (0.64) | 3.69 (0.71) |
| MCS | 2.42 (0.70) | 1.15 (0.73) | 2.56 (0.83) | 2.62 (0.92) |
| HAQ-DI | n=202 | n=187 | n=124 | n=98 |
| −0.25 (0.04) | −0.15 (0.04) | −0.33 (0.04)* | −0.20 (0.05) | |
| DLQI | n=212 | n=189 | n=126 | n=98 |
| −2.28 (0.34)* | −1.24 (0.35) | −2.49 (0.42)* | −0.71 (0.48) | |
| FACIT-F | n=202 | n=189 | n=126 | n=99 |
| −3.67 (0.65) | −2.61 (0.67) | −4.58 (0.80) | −4.49 (0.89) | |
Data are adjusted mean change (SE). *95% CI of difference vs placebo did not cross 0.